Skip to main navigation Skip to search Skip to main content

Phase 1/2a Randomized Double-Blind Placebo-Controlled Study to Evaluate the Safety Tolerability Immunogenicity & Viral Shedding of MEDI-559, A Live Attenuated Intranasal Vaccine Against Respiratory Syncytial Virus in Healthy 1 to <24 Month

Project: Research

Project Details

StatusFinished
Effective start/end date01/25/10 → 05/26/12

Funding

  • MedImmune Incorporated: $3,500.00